


AT₂ (C-18): sc-7420



The Power to Question

BACKGROUND

Angiotensin II (Ang II) is an important physiological effector of blood pressure and volume regulation through vasoconstriction, aldosterone release, sodium uptake and thirst stimulation. Although Ang II interacts with two types of cell surface receptors, AT₁ and AT₂, most of the major cardiovascular effects seem to be mediated through AT₁. Molecular cloning of the AT₁ protein has shown it to be a member of the G protein-associated seven transmembrane protein receptor family. Ang II treatment of cells results in activation of several signal transduction pathways as evidenced by tyrosine phosphorylation of several proteins and induction of others. PLC γ is phosphorylated after 30 seconds of treatment with Angiotensin II, indicating this as an early signal transduction event. Ang II treatment also stimulates phosphorylation of Shc, FAK and MAP kinases, and induces MKP-1, indicating stimulation of growth factor pathways. Ang II stimulation through AT₁ has been shown to activate the JAK/Stat pathway involving a direct interaction between JAK2 and AT₁ as demonstrated by coimmunoprecipitation. The AT₁ receptor has no cytoplasmic kinase domain, but is able to function as a substrate for Src kinases and has several putative phosphorylation sites.

CHROMOSOMAL LOCATION

Genetic locus: AGTR2 (human) mapping to Xq23; Agtr2 (mouse) mapping to X A2.

SOURCE

AT₂(C-18) is an affinity purified goat polyclonal antibody raised against a peptide mapping within a C-terminal cytoplasmic domain of AT₂ of human origin.

PRODUCT

Each vial contains 200 μ g IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-7420 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

AT₂ (C-18) is recommended for detection of AT₂ of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

AT₂ (C-18) is also recommended for detection of AT₂ in additional species, including equine, canine and porcine.

Suitable for use as control antibody for AT₂ siRNA (h): sc-29752, AT₂ siRNA (m): sc-29753, AT₂ shRNA Plasmid (h): sc-29752-SH, AT₂ shRNA Plasmid (m): sc-29753-SH, AT₂ shRNA (h) Lentiviral Particles: sc-29752-V and AT₂ shRNA (m) Lentiviral Particles: sc-29753-V.


Molecular Weight (predicted) of AT₂: 41 kDa.

Molecular Weight (observed) of AT₂: 50 kDa.


STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

DATA



AT₂ (C-18): sc-7420. Western blot analysis of AT₂ expression in mouse liver tissue extract.



AT₂ (C-18): sc-7420. Immunoperoxidase staining of formalin fixed, paraffin-embedded human liver tissue showing cytoplasmic staining of hepatocytes.

SELECT PRODUCT CITATIONS

1. Leri, A., et al. 1999. Up-regulation of AT₁ and AT₂ receptors in postinfarcted hypertrophied myocytes and stretch-mediated apoptotic cell death. *Am. J. Pathol.* 155: 1663-1672.
2. Grammatopoulos, T.N., et al. 2007. Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra. *Mol. Neurodegener.* 2: 1.
3. Mii, A., et al. 2009. Angiotensin II receptor blockade inhibits acute glomerular injuries with the alteration of receptor expression. *Lab. Invest.* 89: 164-177.
4. Clere, N., et al. 2010. Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis. *Int. J. Cancer* 127: 2279-2291.
5. Arce, ME., et al. 2011. Purkinje cells express Angiotensin II AT₂ receptors at different developmental stages. *Neuropeptides* 45: 69-76.
6. da Silva, O.G., et al. 2011. Involvement of the AT₁ receptor in the vasoconstriction induced by angiotensin II in both the inferior vena cava and femoral vein. *Peptides* 32: 112-117.
7. Day, R.M., et al. 2011. Angiotensin II activates AMPK for execution of apoptosis through energy-dependent and -independent mechanisms. *Am. J. Physiol. Lung Cell Mol. Physiol.* 301: L772-L781.
8. Kim, Y.C. and Day, R.M. 2012. Angiotensin II regulates activation of Bim via Rb/E2F1 during apoptosis: involvement of interaction between AMPK β 1/2 and Cdk4. *Am. J. Physiol. Lung Cell. Mol. Physiol.* 303: L228-L238.
9. Anand, U., et al. 2013. Angiotensin II type 2 receptor (AT₂ R) localization and antagonist-mediated inhibition of capsaicin responses and neurite outgrowth in human and rat sensory neurons. *Eur. J. Pain* 17: 1012-1026.

RESEARCH USE

For research use only, not for use in diagnostic procedures.